Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $11.4852W HIGH $21.89
Volume
555.92 K
Value Traded
6.61 M
Short % Float
13.9%
-2.22%Week
+3.58%1 Month
+8.52%3 Month
+38.36%6 Month
-55.05%5 Year
-30.1%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
859.05 M
EPS (TTM)
-0.33
P/E Ratio
-
Ent. Value
748.73 M
Total Shares
44.36 M
Float Shares
42.55 M
Insiders
5.06%
Institutions
106.98%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SIBN Catalyst Timeline
Dated clinical, regulatory and corporate events for SI-BONE, Inc.
Past FDA Catalysts and PDUFA Decisions
How SIBN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
SI-BONE, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every SIBN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Maheshwari AnshulOfficer (Chief Op & Financial Officer) | Sell | -1,731 218,235 held | $19.50 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SIBN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.5 % | 5.36 M | 328.69 K | -12.01% ( -44.87 K) |
SIBN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SIBN ranks across every disease it competes in
Competitive Position is a premium feature
See how SIBN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSIBN News
SIBNSI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis
SI-BONE, Inc. has received FDA 510(k) clearance for its iFuse Granite Onyx System, marking its first product aimed at addressing compromised bone outside the pelvis. This innovative system targets loosening in spinal fusion constructs, particularly for patients with low bone density. The Onyx system aims to enhance osseointegration and reduce revision rates, thereby improving surgical outcomes.
Read more →SIBNSI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
SI-BONE, Inc. will participate in the 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York. The company will host a fireside chat on September 14, 2026, at 8:30 a.m. PT. Investors can register to listen live or access the archived webcast on the company's website.
Read more →SIBNSI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
SI-BONE, Inc. reported a 15.2% increase in worldwide revenue for Q2 2026, totaling $56 million. The company also improved its adjusted EBITDA by 178% to $2.8 million. Despite a net loss of $4.1 million, the firm raised its 2026 revenue guidance, reflecting confidence in its growth strategy and market demand. The upcoming launch of a breakthrough device and favorable reimbursement changes are expected to further enhance revenue.
Read more →SIBNSI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026
SI-BONE, Inc. has announced that it will report its financial results for the second quarter of 2026 on August 3, 2026. The report will be followed by a conference call at 1:30 PM PT. Investors can access the call via registration or through a live webcast on the company's website.
Read more →SIBN▲ +6.9%on this news
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SI-BONE, Inc. will participate in the 2026 Truist Securities MedTech Conference in Boston on June 16, 2026. The company will host a fireside chat at 5:40 a.m. PT. Interested investors can register to listen to the conference call, which will also be available for replay on their website for 90 days post-event.
Read more →SIBN▼ -5.4%on this news· ran to +19% by day 3
SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
SI-BONE, Inc. reported strong financial results for Q1 2026, with worldwide revenue of $52.6 million, an 11.2% increase from the previous year. The company also improved its adjusted EBITDA significantly and raised its revenue guidance for the year. Despite a net loss of $4.3 million, the overall performance indicates a positive trend in growth and market expansion.
Read more →SIBNSI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
SI-BONE, Inc. will participate in the 2026 BofA Securities Healthcare Conference in Las Vegas on May 12, 2026. The company will host a fireside chat to discuss its procedural solutions for compromised bone. Investors can register for the event and access a live audio webcast on the company's website.
Read more →SIBNSI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
SI-BONE, Inc. will report its first-quarter 2026 financial results on May 11, 2026, after market close. A conference call will follow at 1:30 p.m. PT, where investors can register to listen. The company has a strong focus on developing solutions for compromised bone and has conducted over 140,000 procedures since its inception.
Read more →SIBNSI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance
SI-BONE, Inc. reported strong financial results for Q4 2025, with a 15% increase in worldwide revenue and a positive adjusted EBITDA of $5.1 million. The company achieved a 20% revenue growth for the entire fiscal year and provided optimistic guidance for 2026, expecting revenue between $228.5 million and $232.5 million. Despite improvements, SI-BONE continues to face challenges with operating losses and rising expenses.
Read more →SIBNSI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026
SI-BONE, Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference scheduled for March 2, 2026. The company will host a fireside chat at 7:30 a.m. PT. Investors can register for the call and access a live audio webcast on the company's website, which will be archived for 90 days.
Read more →SIBNSI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026
SI-BONE, Inc. will report its financial results for Q4 and the full year of 2025 on February 23, 2026. The announcement includes details about a conference call for investors, which will take place at 1:30 p.m. PT. The company is recognized for its expertise in procedural solutions related to compromised bone.
Read more →SIBNSI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
SI-BONE, Inc. announced preliminary revenue figures for the fourth quarter and full year 2025, estimating worldwide revenue between $200.8 million and $200.9 million, reflecting a growth of about 20%. The company plans to release detailed financial results in late February 2026. However, these figures are preliminary and may undergo significant adjustments pending audit procedures.
Read more →SIBNSI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025
SI-BONE, Inc. announced its participation in the Piper Sandler 37th Annual Healthcare Conference, scheduled for December 2, 2025. The event will feature a fireside chat with management, providing an opportunity for investors to engage. SI-BONE is recognized for its advancements in treating sacropelvic disorders and has a robust clinical evidence base.
Read more →SIBN▲ +16.2%on this news
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance
SI-BONE, Inc. reported a 21% increase in revenue for Q3 2025, reaching $48.7 million, driven by strong demand for its products. The company also improved its adjusted EBITDA to $2.3 million and raised its 2025 revenue guidance to between $198 million and $200 million. However, operating expenses rose by nearly 12%, impacting profitability.
Read more →SIBNSI-BONE To Report Third Quarter 2025 Financial Results on November 10, 2025
SI-BONE, Inc. will announce its third quarter 2025 financial results on November 10, 2025. The company, known for its innovative solutions for sacropelvic disorders, will host a conference call at 1:30 p.m. PT. Investors can register for the call and access the webcast on the company's website.
Read more →SIBNSI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025
SI-BONE, Inc. will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. The company will host a fireside chat to discuss its innovations in treating sacropelvic disorders. Investors can listen to the live webcast and access an archived version for 90 days post-event. SI-BONE is recognized for its pioneering work in minimally invasive SI joint surgery.
Read more →SIBNSI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance
SI-BONE, Inc. reported substantial financial growth in the second quarter of 2025, with a 22% increase in U.S. revenue and a cash flow breakeven status. The company achieved positive Adjusted EBITDA of $1.0 million and an improved net loss of $6.2 million. The firm also announced a leadership transition with the planned retirement of President Tony Recupero, highlighting continued innovation and growing engagement among U.S. physicians. SI-BONE raised its full-year 2025 revenue guidance, anticipating worldwide revenue of $195 million to $198 million.
Read more →SIBNSI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025
SI-BONE, Inc. will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. The event will feature a fireside chat hosted by the company's management. Interested investors can register for the event and access the live audio webcast on the company's website, which will also be archived for later viewing.
Read more →SIBNSI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025
SI-BONE, Inc. has announced that it will report its financial results for the second quarter of 2025 on August 4, 2025, after market close. Management will host a conference call on the same day to discuss the results. The company is recognized for its innovative technologies in surgical treatments for sacropelvic disorders, having supported a significant number of procedures and backed by extensive clinical evidence.
Read more →SIBNSI-BONE to Present at Truist Securities MedTech Conference on June 17, 2025
SI-BONE, Inc. will present at the 2025 Truist Securities MedTech Conference in Boston on June 17, 2025. The company's management will host a fireside chat to discuss their innovations in treating sacropelvic disorders. Investors can register to listen to the conference call and access a replay afterward.
Read more →About SI-BONE, Inc.
Headquarters471 EL CAMINO REAL, SUITE 101, SANTA CLARA, CA, 95050
BIOPHARMAWATCH ELITE PLUS
Trade the next SIBN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime